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Abstract
Introduction: In Alzheimer’s disease, accumulation and pathological aggregation of amyloid β-peptide is
accompanied by the induction of complex immune responses, which have been attributed both beneficial and
detrimental properties. Such responses implicate various cell types of the innate and adaptive arm of the
immunesystem, both inside the central nervous system, and in the periphery. To investigate the role of the
adaptive immune system in brain β-amyloidosis, PSAPP transgenic mice, an established mouse model of
Alzheimer’s disease, were crossbred with the recombination activating gene-2 knockout (Rag2 ko) mice lacking
functional B and T cells. In a second experimental paradigm, aged PSAPP mice were reconstituted with bone
marrow cells from either Rag2 ko or wildtype control mice.
Results: Analyses from both experimental approaches revealed reduced β-amyloid pathology and decreased brain
amyloid β-peptide levels in PSAPP mice lacking functional adaptive immune cells. The decrease in brain β-amyloid
pathology was associated with enhanced microgliosis and increased phagocytosis of amyloid β-peptide aggregates.
Conclusion: The results of this study demonstrate an impact of the adaptive immunity on cerebral β-amyloid pathology
in vivo and suggest an influence on microglia-mediated amyloid β-peptide clearance as a possible underlying mechanism.
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Introduction
Despite the long-held view of the central nervous system
(CNS) as an immune-privileged site, the importance of
local and systemic immunological responses in neurode-
generative brain diseases like Alzheimer’s disease has been
widely recognized in the past few years [1]. In Alzheimer’s
disease, accumulation of misfolded amyloid β-peptide (Aβ)
peptides plays a central role in disease pathogenesis and
has been associated with a wide range of adverse reactions
ultimately leading to neuronal dysfunction and neurode-
generation [2, 3]. Local immune responses to cerebral Aβ
aggregates are a pathological hallmark of Alzheimer’s dis-
ease involving activation of cellular components of the
brain’s innate immunity, such as microglia and astrocytes,
and release of various immune molecules and inflammatory
mediators, including cytokines, acute phase proteins and
factors of the complement cascade, among others [4–7].
This activation of the brain’s innate immune system appears
to be a double-edged sword as it has been related to both
beneficial and detrimental consequences [8]. Microglia, the
resident phagocytes of the CNS, for example, are able to
bind to Aβ via various cell-surface receptors and promote
phagocytosis and clearance of Aβ aggregates [5]. Their
chronic activation in Alzheimer’s disease, however, has also
been associated with disturbed clearance functions and an
increased production of pro-inflammatory and neurotoxic
factors, which may further promote neuronal injury and
exacerbate neuronal loss [9].
In contrast to the activation of the brain’s innate im-
mune system, the role of the adaptive immunity in cere-
bral β-amyloidosis appears to be much less prominent
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and is still incompletely understood. Consistent with a
role of the humoral adaptive immunity in Alzheimer’s
disease pathogenesis, misfolded Aβ peptides have been
shown to induce specific B cell-mediated immune re-
sponses, with naturally occurring autoantibodies against
Aβ being found in the cerebrospinal fluid (CSF) and
blood of affected patients, as well as, healthy individuals
[10–17]. Interestingly, these autoantibodies seem to share
conformation-specific binding epitopes and the ability
to promote microglia-mediated clearance of β-amyloid
plaques, as well as to lower neurotoxicity [12, 18–20]. In
support of these findings, Britschgi and colleagues demon-
strated that naturally occurring autoantibodies against a
broad range of amyloidogenic peptides can display neuro-
protective activities [21], with similar findings being re-
ported by other investigators [22, 23]. Apart from the
involvement of B cell-mediated humoral immune re-
sponses, several authors have begun addressing the role of
the cellular adaptive immunity in Alzheimer’s disease. Pre-
vious neuropathological analyses repeatedly confirmed the
presence of T cells in post-mortem Alzheimer’s disease
brains [14, 24–29]. Moreover, Aβ-reactive T cells were
readily detectable in the peripheral blood of Alzheimer’s
disease patients and healthy elderly subjects, in whom
their proportion was significantly increased in comparison
to middle-aged control individuals [30]. Analysis of the
profile of specific lymphocyte subsets led to ambiguous
findings. Richart-Salzburger, for example, reported a sig-
nificant decrease of CD3+ CD8+ and CD19+ lymphocytes
in the peripheral blood of Alzheimer’s disease patients,
suggesting a general decline of the adaptive immunity in
disease pathogenesis [31]. Other authors, in contrast, ob-
served significant increases in activated CD4+ and CD8+ T
cell subsets in peripheral blood [32–35]. Recently, Lueg
et al. also assessed alterations of T cell subsets in the intra-
thecal compartment of cognitively impaired and cogni-
tively intact elderly subjects as well as healthy younger
control individuals and found a significantly increased
proportion of CD8+ lymphocytes in the CSF of patients
with Alzheimer’s disease – but not in patients suffering
from other dementias – which correlated with cognitive
deficits [33]. Altogether, these results provided further
evidence for an involvement of the adaptive immunity in
Alzheimer’s disease.
In this study, we addressed the role of a congenital
deficiency of the adaptive immune system on β-amyloid-
related pathology in vivo and generated B and T cell-
ablated APP transgenic mice by crossbreeding the PSAPP
mice, en established mouse model of Alzheimer’s disease
[36], with the recombination activating gene-2 knockout
(Rag2 ko) mice lacking functional B and T lymphocytes
[37]. In a second experiment, the effects of an acquired
deficiency of the adaptive immunity were studied in lethally
irradiated aged PSAPP mice reconstituted with Rag2 ko
bone marrow. Our results from both experimental para-
digms demonstrate an impact of functional adaptive im-
mune cells on cerebral β-amyloid deposition in vivo and
suggest an increased Aβ clearance, likely mediated by
microglial cells, as a possible mechanism underlying
reduced Aβ pathology in the absence of functional B
and T cells.
Materials and methods
Animals and tissue processing
The Rag2 ko mouse lines [37] and the wildtype (WT)
mouse line expressing the Ptprca (CD45.1 or Ly5.1) allele
(Model 4007) were purchased from Taconic (Ry, Denmark).
The PSAPP transgenic mice express a chimeric mouse/
human amyloid precursor protein (Mo/HuAPP695swe)
and a mutant human presenilin 1 (PS1-dE9) and were
purchased from the Jackson Laboratory (Maine, USA)
[36, 38]. All mice were on the C57Bl/6 (H2b) genetic back-
ground. Rag2 ko mice (Model RAGN12; immunopheno-
type H2b (C57B/6), CD45.2) were crossed with the PSAPP
mice (immunophenotype H2b (C57B/6), CD45.2) to gen-
erate the four genotypes PSAPP/Rag2 ko, PSAPP, Rag2 ko
and WT in the F2 generation. For adoptive bone marrow
(BM) transfer experiments, Rag2 ko donor mice express-
ing the immunophenotype H2b (C57B/6), CD45.1 were
used (Model 461). All mice were housed in groups
(two to five animals per cage in 396 × 215 × 172 mm
cages (Indulab, Gams, Switzerland)) under specific patho-
gen free (SPF) conditions at 22 °C ±1 °C and a 12 h light–
dark cycle beginning at 7:00 AM. The health status of ani-
mals was monitored twice a week except for the BM-
transferred mice, which were monitored every second day
during the first two weeks after irradiation. No major ad-
verse events were observed. Water and food were pro-
vided ad libitum except for the time of cognitive testing.
Environmental enrichment included bedding, one card-
board mouse house and a paper tissue as nesting material.
For all biochemical and histological analyses gender-
balanced groups of mice were used. Mice were deeply anes-
thetized with ketamine/xylazine. Blood samples were col-
lected from the right ventricle in ethylenediaminetetraacetic
acid (EDTA)-coated tubes (Sarstedt, Sevelen, Switzerland)
and centrifuged for plasma preparation at 2000 g for
10 min at 4 °C. Following the collection of blood, mice were
transcardially perfused with ice-cold phosphate buffered sa-
line (PBS) and their brains rapidly removed. Brains were
dissected into two hemispheres with the left hemisphere be-
ing placed in 4 % (w/v) paraformaldehyde (PFA) in PBS,
post-fixed overnight in the same medium at 4 °C and trans-
ferred into a 30 % sucrose solution (in PBS) for 72 h (cryo-
protection). The right hemisphere was snap frozen and
stored at −80 °C for later biochemical analysis.
All animal experiments were performed in compliance
with Swiss law for care and use of animals (“455.163
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Tierversuchsverordnung” 2010) and were approved by the
veterinarian authorities of the Canton of Zurich (license
numbers 079/2010 and 102/2013). All sections of this
report adhere to the ARRIVE guidelines for reporting ani-
mal research [39]. A complete ARRIVE guidelines check-
list is included.
Protein extracts and Western blotting
Homogenization of brain tissue was performed using a
glass Teflon homogenizer in fivefold wet weight amount
of buffer A (100 mM Tris–HCl, 150 mM NaCl, Phos-
phatase Inhibitor Cocktails 2 + 3 (Sigma-Aldrich, Buchs,
Switzerland) and Complete Protease Inhibitor Cocktail
(Roche Diagnostics, Rotkreuz, Switzerland)). Superna-
tants were collected (=Tris fraction) after centrifugation
at 100’000 g for 1 h. The pellets were rehomogenized in
buffer A containing 2 % sodium dodecyl sulfate (SDS).
Centrifugation was repeated and supernatants again
were again collected (=SDS fraction). The resulting pel-
lets were dissolved in 70 % formic acid (FA), sonicated
two times for 30 s at 30 % power, ultracentrifuged at
100’000 g for 30 min, supernatants extracted, lyophilized
and reconstituted in buffer A for further analysis. Extracts
were separated by SDS-polyacrylamide gel electrophoresis,
blotted onto nitrocellulose, blocked in Tris-buffered saline
containing 5 % milk for 1 h at room temperature. Blots
were incubated with the primary antibody overnight
at 4 °C, then visualized via peroxidase-conjugated
antibody and ECL reaction (Amersham Biosciences,
Otelfingen, Switzerland). The primary rabbit poly-
clonal antibody anti-C-terminal APP (Sigma-Aldrich
Chemie GmbH, Buchs, Switzerland) was used at a
1:2000 dilution. A mouse monoclonal anti-GAPDH
antibody (Meridian Life Science, Memphis, USA) was used
as internal loading control and for normalization of densi-
tometric analyses of the immunoreactive bands (dilution
1:10’000). Image J software (rsb.info.nih.gov/ij/) was used
for quantifications of the immunoreactive bands by densi-
tometry of the scanned films under conditions of non-
saturated signal.
Meso Scale Discovery (MSD) analysis
Aβ40 and Aβ42 levels were measured in the above-
mentioned brain homogenate fractions and plasma using
an MSD 3plex multi-SPOT Aβ human kit (Gaithersburg,
MD, USA) as previously described [40]. Plates were
measured on an MSD SECTOR Imager 600 plate
reader (Gaithersburg, MD, USA) after adding the MSD
Read Buffer T (Gaithersburg, MD, USA). The MSD
DISCOVERY WORKBENCH software (Version 3.0.17)
(Gaithersburg, MD, USA) with Data Analysis Toolbox
was used to calculate sample concentrations by com-
paring them against a standard curve.
Histological analysis
PFA-fixed and cryoprotected hemibrains were cut con-
tinuously into 35 μm thick coronal slices at −20 °C using
a microtome (Leica Jung HN40, Leica Microsystems AG,
Heerbrugg, Switzerland) and stored at −20 °C in an anti-
freeze solution (phosphate buffer 0.50 M in MilliQ
water: ethyleneglycol: glycerol = 1.3:1:1) until use. For
each staining six equidistant sections per mouse were
analyzed from positions −1.94 mm to +1.70 mm from
the bregma [41]. For immunohistochemistry, sections
were first washed with PBS + 0.2 % Triton X-100,
blocked with appropriate normal sera for 1 h and incu-
bated with the primary antibody overnight at 4 °C. The
following primary antibodies were used: Glial fibrillary
acidic protein (GFAP; 1:400 dilution; rabbit polyclonal;
Sigma-Aldrich Chemie GmbH, Buchs, Switzerland), Ion-
ized calcium binding adaptor molecule 1 (Iba1; 1:500 di-
lution; rabbit polyclonal; Wako Chemicals, Osaka, Japan)
and anti-β amyloid 1–16 (clone 6E10; 1:500 dilution;
mouse monoclonal; BioLegend, Fell, Germany). Second-
ary antibodies were obtained from Jackson Immunore-
search Laboratories (West Grove, PA, USA). Thioflavin
S staining was performed according to the standard pro-
tocols as previously described [42]. 4′,6-Diamidin-2-
phenylindol (DAPI; Sigma-Aldrich Chemie GmbH,
Buchs, Switzerland) was used as counterstaining agent.
For quantitative image analysis, the cortex (including the
cingulate, motor and somatosensory cerebral cortex) was
analyzed on six equidistant coronal hemibrain sections
from positions −1.94 mm to +1.70 mm from the bregma
[41]. Mean values per mouse were calculated and included
into statistical analysis. Average plaque numbers refer to
single hemibrain sections. Quantitative image analysis was
performed blinded using ImageJ software (rsb.info.nih.
gov/ij/). For specific microglial analyses around amyloid
plaques serial confocal Z-stack images, comprising an
average of 30 to 40 cortical brain sections at 0.26 μm in-
tervals, were acquired using a confocal laser scanning
microscope (Leica TCS SP8, Leica Microsystems AG,
Heerbrugg, Switzerland). On average, 12 cortical Thiofla-
vin S-positive amyloid plaques per mouse were analyzed.
Plaques of an average size between 20 and 30 μm were
randomly selected by the blinded investigator between
cortical layers II and V on six consecutive equidistant sec-
tions (2 plaques per section) from positions −1.94 mm to
+1.70 mm from the bregma [41]. Counting of microglia
was done in a diameter of 100 μm around the center of
the amyloid plaque as previously described [43].
Adoptive bone marrow transfer
For the generation of bone marrow (BM) chimeras,
12 month-old PSAPP transgenic recipient mice (CD45.2;
12 females and 7 males) were lethally irradiated with
two doses of 600 rads each (second irradiation after
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12 h). 3 month-old Rag2 ko (Model 461, Taconic, Ry,
Denmark) and age-matched WT control donor mice
(Model 4001, Taconic, Ry, Denmark) expressing the
CD45.1 allele were sacrificed by CO2 inhalation, and
bones (including femur, tibia and pelvis) were flushed with
sterile PBS to obtain BM stem cells. A total of 5 x 106 cells
in 0.2 ml sterile Hank’s Buffered Salt Solution (HBSS, Life
Technologies, Zug, Switzerland) were injected i.v. per ani-
mal in a randomized and gender-balanced fashion (10
PSAPP mice (including 6 females and 4 males) received
Rag2 ko BM; 9 PSAPP mice (including 6 females and 3
males) received WT BM). BM reconstitution of recipient
mice was carried out with BM from gender-matched do-
nors. Autoclaved drinking water supplemented with anti-
biotics was provided for two weeks (2 g/l Neomycin
sulphate; Sigma Aldrich). Reconstitution efficiency with
CD45.1 positive cells was assessed on the day of sacrifice
(6 months later) by flow cytometry of EDTA whole blood
samples.
Flow cytometry
Ammonium-Chloride-Potassium (ACK) lysis of red
blood cells was performed on EDTA blood samples
followed by HBSS and FACS buffer (HBSS, 2 % fetal calf
serum (FCS), 10 mM EDTA, 0.01 % NaN3) washing steps.
After using a live/dead exclusion dye (Molecular Probes,
Eugene, OR, USA) an Fc blocking step (anti-mouse
CD16/32, TruStain fcX™, Biolegend, CA, USA) was used
to reduce non-specific binding. The cells were then
stained for 15 min at 4 °C with surface marker-specific
antibodies: anti-CD45 (PE conjugated, rat anti-mouse,
clone 30-F11, BioLegend, Fell, Germany), anti-CD45.1 (PE
conjugated, mouse anti-mouse, clone A20, BioLegend,
Fell, Germany), anti-CD45-2 (FITC conjugated, mouse
anti-mouse, clone 104, BioLegend, Fell, Germany), anti-
CD11b (APC or APC-Cy7 conjugated, rat anti-mouse/
human, clone M1/70, BioLegend, Fell, Germany), anti-
CD4 (FITC or APC conjugated, rat anti-mouse, clone
RM4-5, BioLegend, Fell, Germany), anti-Ly6C (FITC con-
jugated, rat anti-mouse, clone AL-21, BD Biosciences,
Allschwil, Switzerland), anti-Ly6G (APC-conjugated, rat
anti-mouse, clone 1A8, BioLegend, Fell, Germany) and
anti-B220/CD45R (PerCP-Cy5.5 or APC-Cy7 conjugated,
rat anti-mouse/human, clone RA3-6B2, BioLegend, Fell,
Germany). After additional washing with FACS buffer
samples were analyzed blinded using a BD LSRFortessa™
cell analyser (BD Biosciences, Allschwil, Switzerland). Sin-
gle stainings and isotype control antibodies were included
as controls.
Cognitive-behavioral testing
A battery of validated tests was used to assess motoric
and cognitive behavior of the mice. For all cognitive
tests, the state-of-the-art ANY-maze Video Tracking
System software (Stoelting Co., USA) was used as an au-
tomated system to track animal movements and comple-
tion of test specific tasks. All animals were tested naïve
in a random order. The tested groups were balanced for
gender. The experimenter was blinded during the time
of testing.
Open Field
The Open Field test measures locomotor activity and
anxiety. Mice were placed in the centre of a white box
(49 x 49 x 33 cm) with indirect illumination (22 Lux) and
their movements were tracked for 15 min. Distance trav-
elled, average speed and time spent in the central (inner
square 33 x 33 cm) versus peripheral zones of the open
field were calculated using the ANY-maze software [44].
Novel Object Recognition Test (NORT)
This test measures memory retention and recognition
memory in mice and was performed in accordance to
published protocols [45]. The NORT has been designed
as a two-trial task including a sample trial (ST) and a
test trial (TT) and was performed following the Open
Field test with a delay of 5 min in the same box. During
ST, two similar objects were placed in the box, 34 cm
apart (symmetrically). Each animal was allowed to ex-
plore the box for 5 min. The animals were considered to
be exploring the object when the head of the animal was
within a defined area of 12 cm in diameter around the
object. The objects sizes ranged within diameters from
3–4 cm, so the animal was considered exploring the ob-
ject when the animals head was near the object as close
as 4 cm. After ST, mice were immediately returned to
their holding cages and following a 10 min delay TT was
carried out. One of the objects used during ST was re-
placed by a novel one differing in form and color before
each mouse was placed back into the same box as dur-
ing ST. The mice were then allowed to freely explore for
5 min and the time spent exploring each object was re-
corded. The ratio was calculated by dividing measures of
the new object versus the old one.
Y-Maze
The Y-Maze was used to evaluate spatial working mem-
ory in mice and was carried out according to published
protocols [40]. The Y-Maze consists of three horizontal
arms (40 cm long, 11 cm wide and 21 cm high) symmet-
rically disposed at 120° to each other. Light was adjusted
to 28 Lux. The mice were placed at one end of the first
arm and then allowed to freely explore for 5 min. The
mice were tracked recording arm entries and exploration
time in each arm. The total number of arm entries was
measured as an index of locomotor activity to rule out
the interference of changes in motility with the parame-
ters of learning and memory [46, 47]. The percentage
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alternation was calculated as the ratio of actual to pos-
sible alternations (defined as the total number of arm
entries −2) x 100 %.
Statistical analysis
The primary experimental outcome of our study in-
cluded Aβ pathology (amyloid plaque pathology, Aβ
levels) and glial pathology. Secondary outcome measures
included cognitive performance and APP processing.
Data analysis was performed using the SPSS software
version 19.0 (16 M, Zurich, Switzerland). Extreme values
according to SPSS explorative data analysis were ex-
cluded from further analysis. Tests for normal distribu-
tion were performed before statistical testing. According
to the results of the Shapiro-Wilk- and the Kolmogorov-
Smirnov-Test for normality, either two-sample Stu-
dent’s t-test or two-tailed Mann–Whitney-U-Test for
two sample groups or ONEWAY ANOVA or the
Kruskal-Wallis-Test for multiple group comparisons
(followed by post-hoc Bonferroni or Mann–Whitney-
U-Tests with Bonferroni correction) were performed.
For NORT a Wilcoxon-Test was performed to test if
the ratio differed significantly from 1. For Y maze a one-
sample t-test was performed to test if the percentage of cor-
rect alternations was significantly above 50. A p-value <0.05
was considered statistically significant. *p < 0.05, **p < 0.01,
***p < 0.001 indicate significantly different performances.
Error bars represent SEM.
Results
Reduced β-amyloid pathology in PSAPP mice with a
congenital deficiency of the adaptive immunity
To investigate the effects of a specific congenital abla-
tion of functional B and T cells on Aβ-related pathology
in vivo, bigenic PSAPP mice expressing mouse/human
amyloid precursor protein (Mo/HuAPP695swe) and mu-
tant presenilin 1 (PS1-dE9) under the control of the
mouse prion protein (PrP) promoter were crossed with
the Rag2 ko mice. B and T cell-ablated PSAPP/Rag2 ko
mice were analyzed together with immunocompetent
PSAPP transgenic mice, non-transgenic Rag2 ko mice and
WTcontrol mice at two different ages. As expected, FACS
analysis of whole blood confirmed the absence of func-
tional lymphocytes in the two Rag2 ko mouse lines, Rag2
ko and PSAPP/Rag2 ko (Additional file 1: Figure S1).
Notably, B and T cell numbers were similar between
WT and the PSAPP transgenic mice, and no significant
differences were observed in the systemic myeloid com-
partment among the four genotypes (Additional file 1:
Figure S1). Histological analysis at 3 months of age
(pre-plaque stage) showed no detectable amyloid plaque
deposition in the Rag2-deficient PSAPP/Rag2 ko mice,
nor in age-matched PSAPP mice; quantitative MSD ana-
lysis of cortical brain extracts and plasma revealed similar
Aβ levels in the two genotypes at 3 months (Additional
file 2: Figure 2). In contrast, at 8 months of age, Thiofla-
vin-S stainings for fibrillar Aβ deposits (Fig. 1a, b) and
immunostainings with the monoclonal anti-Aβ antibody
6E10 (data not shown) demonstrated abundant amyloid
plaque pathology in the PSAPP mice which was signifi-
cantly reduced in age-matched PSAPP/Rag2 ko mice. The
25–30 % reduction in amyloid plaque load and Aβ plaque
numbers in the B and T cell-deficient PSAPP/Rag2 ko mice
was accompanied by a marked decrease in soluble and in-
soluble brain Aβ40 and Aβ42 levels and paralleled by a
mild increase in plasma Aβ42 in comparison to the PSAPP
mice (Fig. 1a–c). These effects on Aβ pathology were asso-
ciated neither with changes in APP expression nor with
changes in APP processing, as revealed by Western blot
analyses, suggesting that the reduction in Aβ load and Aβ
levels was unlikely to be mediated by altered Aβ production
(Additional file 3: Figure S3).
Glial responses and cognitive behavior in Rag2-deficient
PSAPP mice
To assess whether the reduction in Aβ pathology in
8 month-old PSAPP/Rag2 ko mice was associated with
changes in glial cell responses, GFAP immunostainings
for astrocytes and Iba1 stainings for microglia were per-
formed. No significant differences in astroglia and
microglial cells were observed among the four genotypes
at the age of 3 months (Additional file 4: Figure S4). In
8 month-old animals, as anticipated, the degree of astro-
gliosis and microgliosis was significantly increased in the
plaque-bearing PSAPP and PSAPP/Rag2 ko mice as
compared to WT and Rag2 ko mice (Fig. 2a–d). The ob-
served decrease in amyloid pathology in the PSAPP/
Rag2 ko mice was accompanied by a significantly re-
duced GFAP immunoreactivity in comparison to the
PSAPP mice (Fig. 2a, b). In contrast, Iba1 immunoreac-
tivity appeared similar between the PSAPP/Rag2 ko and
the PSAPP mice, suggesting a relative increase in β-
amyloid-related microgliosis in the absence of functional
B and T cells (Fig. 2c, d).
To test whether B and T cell ablation and the observed
effects on Aβ pathology in the PSAPP/Rag2 ko had any in-
fluence on cognitive outcome measures, we analyzed
hippocampal-dependent cognitive performance in the four
genotypes (WT, PSAPP, Rag2 ko and PSAPP/Rag2 ko).
Spatial working memory was assessed in the Y maze, while
recognition memory was tested in the Novel Object Recog-
nition Task (NORT). At 8 months of age, PSAPP transgenic
mice were characterized by significant impairments on both
cognitive tasks in comparison to age-matched WT control
mice (Fig. 3a, b). In line with previous reports showing re-
duced cognitive performance in mice lacking functional
adaptive immune cells [48–50], similar results were ob-
served for both immunocompromised mouse lines (Rag2
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ko and PSAPP/Rag2 ko) independent of the APP transgene
expression (Fig. 3a, b).
Reduced amyloid pathology in PSAPP mice with an
acquired deficiency of the adaptive immune system
Building on our results in the PSAPP/Rag2 ko mice lack-
ing functional B and T cells from birth, we next sought
to determine the effects of an acquired deficiency of the
adaptive immunity on established Aβ-related pathology
in the PSAPP model of β-amyloidosis. To achieve this
goal, bone marrow (BM) chimeric mice were generated
by adoptive transfer of BM cells from Rag2 ko and WT
control mice into 12 month-old lethally irradiated
PSAPP mice (Fig. 4a). FACS analysis of whole blood
6 months after BM transfer showed a fivefold reduction
of mature B (B220+) and T (CD4+) lymphocytes in the
Rag2 ko BM-reconstituted PSAPP mice, thus confirming
the successful reduction of adaptive immune cells in this
model (Fig. 4b). Histopathological analysis of Thioflavin-
S-stained brain sections from 18 month-old mice re-
vealed a similar amyloid burden between the WT BM-
grafted PSAPP mice and the Rag2 ko BM-transferred
PSAPP mice, suggesting that reconstitution with B and
T cell-deficient BM had no significant impact on com-
pact fibrillar Aβ deposits in this model (Additional file 5:
Figure S5 A, B). Immunostainings with the monoclonal
antibody 6E10, however, which recognizes a wide range
of Aβ aggregates including diffuse Aβ deposits, showed
a significantly reduced (around 35 %) Aβ plaque load,
but no change in Aβ plaque numbers in the Rag2 ko
BM-transferred PSAPP mice in comparison to WT
BM-reconstituted mice (Fig. 5a, b). This reduction in
6E10-stained Aβ load was associated with a significant
decrease in detergent insoluble (FA soluble) cortical
brain Aβ40 and Aβ42 levels and a parallel increase in
plasma Aβ40 and Aβ42 (Fig. 5c).
Increased microgliosis and enhanced Aβ phagocytosis in
PSAPP mice reconstituted with Rag2 ko BM
Similar to our findings in the crossbred mice, the reduc-
tion in Aβ pathology in the Rag2 ko BM-reconstituted
Fig. 1 Reduced amyloid pathology and reduced Aβ levels in
8 month-old PSAPP/Rag2 ko mice in comparison to age-matched
PSAPP mice. a, b Quantitative analysis of Thioflavin S stainings shows a
25 % reduction in amyloid load and amyloid plaque number in the B
and T cell-ablated PSAPP/Rag2 ko mice as compared to the PSAPP mice
with a functional adaptive immune system (representative images of
cortical stainings are shown in (a)). Scale bar = 300 μm. ***p< 0.001.
n= 13–15 per group. c Quantitative MSD analysis of Aβ40 and Aβ42 in
plasma and cortical brain extracts shows a significant reduction in Tris
soluble, SDS detergent soluble and formic acid soluble Aβ40 and Aβ42
levels in the PSAPP/Rag2 ko mice as compared to the PSAPP mice. The
reduction in brain Aβ levels is accompanied by a significant increase in
plasma Aβ42. *p< 0.05. **p< 0.01. ***p< 0.001. n= 9–14 per group
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PSAPP mice was not associated with changes in levels of
full-length APP nor in changes of APP C-terminal frag-
ments, again suggesting that the acquired deficiency in
functional B and T cells did not influence Aβ levels by
affecting APP metabolism (Additional file 6: Figure S6).
To determine whether the reduction in Aβ pathology
in the PSAPP mice reconstituted with Rag2 ko BM was
associated with altered cellular responses of the brain’s
innate immune system, GFAP and Iba1 immunostain-
ings were performed 6 months after BM reconstitution
Fig. 3 Impaired hippocampal memory performance in the PSAPP transgenic mice and both Rag2 ko-deficient mouse lines in comparison to the
WT control. a Y maze performance was evaluated by correct alternations in %. b Recognition memory in the novel object recognition task (NORT)
was measured by comparing the time spent with the novel and the familiar object. In the Y maze and the novel object recognition task performance
was compared to chance level (50 % and 1, respectively). Significant differences are shown. *p < 0.05. n = 9–21 per group
Fig. 2 Glial responses in the absence of functional B and T cells at 8 months. a, b GFAP immunohistological analysis for astrocytes and (c, d) Iba1
immunostaining for microglia reveal significant increases in microgliosis in the amyloid-depositing APP transgenic mice (PSAPP/Rag2 ko and
PSAPP) in comparison to the non-transgenic Rag2 ko and WT mice. GFAP immunoreactivity (b) – but not Iba1 immunoreactivity (d) – is significantly
reduced in the PSAPP/Rag2 ko mice as compared to the PSAPP mice (representative images of cortical stainings are shown on the left). Scale
bar = 300 μm (Insert: Scale bar = 40 μm). *p < 0.05. ***p < 0.001. n = 10–14 per group
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(at 18 months of age). Quantitative immunostochemical
analysis showed similar astrogliosis between WT and
Rag2 ko BM-transferred PSAPP mice (Fig. 6a, b), but a
significant increase in microglial cells in the Rag2 ko
BM-recipient mice (Fig. 6c, d). Confocal microscope
analysis of Iba1-positive cells decorating Thioflavin
S-stained amyloid plaques, which were matched for
size, revealed a trend towards elevated average numbers
of plaque-associated microglia in the Rag2 ko BM-
transferred PSAPP mice in comparison to the WT
BM-recipient mice (Additional file 7: Figure S7 A, B). Im-
portantly, both the number of Aβ-phagocytosing microglia
and the total volume of the phagocytosed Thioflavin
S-positive material per plaque were significantly increased
in the PSAPP mice reconstituted with Rag2 ko BM,
suggesting enhanced Aβ phagocytosis in the absence of
functional T and B cells (Fig. 7a, b).
Discussion
The ageing process is a major risk factor for sporadic
Alzheimer’s disease and impacts negatively on an indi-
vidual’s capacity to respond to immune challenges, a
condition termed immunosenescence [51]. Human
immunosenescence is accompanied by a deterioration of
B and T cell-mediated adaptive immune responses, while
innate immunity is rather preserved or even upregulated
[51]. An even more pronounced reduction in systemic T
and B cells has previously been reported by some authors
in patients with Alzheimer’s disease [31], suggesting a
“premature immunosenescence” phenotype specifically af-
fecting adaptive immunity in the pathogenesis of the dis-
ease [52]. In the present study, we applied two different
experimental paradigms to investigate the contribution of
the adaptive immune system to cerebral β-amyloid path-
ology in an established APP transgenic mouse model of
Alzheimer’s disease. The consequences of a congenital de-
ficiency of the adaptive immunity were assessed in the
PSAPP/Rag2 ko crossbred mice which were compared to
immunocompetent PSAPP mice. To confirm the absence
of T and B cells in this model and exclude potential effects
of APP/mutant presenilin 1 on systemic immune com-
partments in the PSAPP mice [53], FACS analyses of
whole blood as well as other peripheral immune organs
(data not shown) were performed. Notably, no significant
alterations of peripheral lymphocytes and myeloid cells
were observed between PSAPP transgenic and WTcontrol
mice, thus excluding major systemic immune alterations
in this model. Histological and biochemical analyses re-
vealed a reduced β-amyloid pathology along with de-
creased brain Aβ levels in aged PSAPP/Rag2 ko mice in
comparison to the PSAPP mice after onset of amyloid
plaque deposition. This decrease in Aβ pathology was as-
sociated with an increase in plasma Aβ levels and a rela-
tive increase in Iba1-positive microglial cells, which was
not observed in 3 month-old pre-plaque PSAPP/Rag2 ko
mice, suggesting that the reduction in brain Aβ in the ab-
sence of functional B and T cells only occurred in the
presence of Aβ plaque deposits and was likely mediated
by amyloid-reactive microglia. In line with these findings,
similar results were obtained in our second model system
of an acquired adaptive immune deficiency: aged PSAPP
mice reconstituted with Rag2 ko BM cells showed a re-
duced β-amyloid load, decreased brain Aβ and elevated
plasma Aβ levels along with increased microgliosis and el-
evated numbers of plaque-associated Aβ-phagocytosing
microglia. In contrast to our findings in the PSAPP/Rag2
ko crossbred mice, reconstitution of PSAPP transgenic
mice with Rag2 ko BM resulted in milder effects on Aβ
pathology, as revealed by a reduced 6E10-stained Aβ load,
but no change in Thioflavin S-stained compact fibrillar Aβ
deposits, decreased brain Aβ levels exclusively in the de-
tergent insoluble protein fraction and similar levels of β-
amyloid-associated astrogliosis as compared to the WT
BM-recipient PSAPP controls. In our opinion, the ob-
served milder effects on Aβ pathology may at least partly
be explained by the incomplete ablation of T and B cells
in the BM transfer paradigm (versus a complete ablation
of lymphocytes in the crossbreeding approach). Moreover,
additional aspects, e.g. the older age of PSAPP transgenic
mice in the BM transfer experiment and/or shorter
Fig. 4 Bone marrow (BM) transfer experiment. a 12 month-old PSAPP mice (immunophenotype H2b, CD45.2) were lethally irradiated with two
doses of 600 rads, then reconstituted with 5 x 106 BM cells from either Rag2 ko or WT donor mice (immunophenotype H2b, CD45.1). b 6 months
after transplantation, Rag2 ko BM recipients showed a fivefold reduction in B cells and CD4+ T cells, as determined by FACS staining of CD45+ blood
leukocytes with antibodies against CD4 and the pan B-cell marker B220. **p < 0.01. ***p < 0.001 . n = 9–10 per group
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Fig. 5 Reduced Aβ load in PSAPP mice reconstituted with Rag2 ko
BM a, b). Quantitative analysis of free-floating sections stained with
the monoclonal anti-Aβ antibody 6E10 shows a 35 % reduction in the
Aβ-immunoreactivity, but no significant change in Aβ-immunoreactive
plaque number, in Rag2 ko BM-transferred PSAPP mice as
compared to WT BM-transferred PSAPP mice 6 months after
reconstitution (at 18 months of age; representative images of
cortical stainings are shown in (a)). Scale bar = 300 μm. *p < 0.05.
n = 8–10 per group. (c) Quantitative MSD analysis of plasma and
cortical brain extracts reveals a significant reduction in formic
acid soluble Aβ40 and Aβ42 along with an increase in plasma
Aβ levels in PSAPP mice transferred with Rag2 ko BM in
comparison with WT BM-transferred PSAPP mice. *p < 0.05.
n = 9–10 per group
Fig. 6 Glial responses in PSAPP mice reconstituted with WT and
Rag2 ko BM. a Astrogliosis is unchanged in Rag2 ko BM-transferred
mice in comparison to WT BM-transferred PSAPP mice 6 months
after reconstitution (at 18 months; representative images of cortical
stainings are shown on the left). b Quantitative analysis of GFAP
immunostainings. c, d Iba1 immunohistological analysis reveals a
significant increase in microgliosis in Rag2 ko BM-recipient PSAPP mice
in comparison to WT BM-transferred PSAPP mice. Scale bar = 300 μm
(Insert: Scale bar = 40 μm). *p < 0.05. n = 8–10 per group
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follow-up periods (6 months versus 8 months in the cross-
breeding approach) have to be taken into account.
In our experimental set up Rag2 ko mice with a com-
bined T and B cell deficiency were used. This approach
allowed us to simulate the conditions of “premature
immunosenescence” in a mouse model of cerebral β-
amyloidosis and investigate the effects of a general adap-
tive immune deficiency on Aβ pathology. Based on this
experimental design, however, we were not able to delin-
eate a specific lymphocyte subpopulation accounting for
the effects on microglia and cerebral amyloid deposition.
Although we cannot exclude that a lack of B cell-
mediated humoral immunity might have contributed to
the observed effects, this possibility appears to be less
likely in our view for several reasons. On the one hand,
B cells, unlike T cells, have not been detectable in brain
parenchyma of Alzheimer’s disease patients [54] nor in
brains of PSAPP transgenic mice, as revealed by immuno-
histochemistry and brain FACS analysis (Ferretti et al.,
submitted). On the other hand, based on several previous
studies suggesting a role for naturally occurring Aβ auto-
antibodies in restricting brain amyloidosis [12, 18–20], a
lack of Aβ-reactive B cells would probably be expected to
result in exacerbated rather than reduced amyloid path-
ology. In line with this notion, progressive age-related
amyloid plaque deposition was previously associated with
a specific reduction of naturally occurring serum Aβ auto-
antibodies in the Tg2576 APP transgenic mouse model of
Alzheimer’s disease [55]. In contrast to B cells, T cells have
been repeatedly detected as infiltrating brain tissue both
in human Alzheimer’s disease brains and in animal models
of the disease [24–29, 56, 57] Ferretti et al., submitted).
Although the exact role of T lymphocytes in the disease
process remains incompletely understood, both proin-
flammatory and neurotoxic as well as antiinflammatory
and neurotrophic mechanisms have been attributed to
their presence in brain parenchyma [58]. In certain rat and
APP transgenic mouse models of Alzheimer’s disease, for
example, specific effector CD4+ T cells secreting IFN-γ, IL-
17 or IL-22 were linked to increased neuroinflammation
Fig. 7 Increased number of Aβ-phagocytosing microglia in the Rag2 ko BM-reconstituted PSAPP mice. a Representative maximum projection
confocal image (left panel) of a plaque-associated microglial cell containing Thioflavin S-positive Aβ material (arrowhead). Image shows microglia
(Iba1, red) and amyloid deposits (Thioflavin S, green). Nuclei were counterstained by DAPI (blue). Orthogonal views of z-stack images are shown
in the right panel. Scale bar = 20 μm (b) significantly increased number of amyloid plaque-associated Iba1-positive microglial cells containing
Thioflavin S-positive Aβ material in the Rag2 ko BM-recipient PSAPP mice. *p < 0.05. n = 9 mice per group (on average 12 plaques per mouse
analyzed) (c) significantly increased total volume of phagocytosed Aβ material in the Rag2 ko BM-reconstituted PSAPP mice in comparison to the
WT BM-recipient control mice. *p < 0.05. n = 9 mice per group (on average 12 plaques per mouse analyzed)
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and exacerbation of disease progression [59, 60]. In other
animal studies, however, IFN-γ-dependent targeting of Aβ-
specific Th1-polarized CD4+ cells to amyloid plaques was
shown to reduce amyloid pathology without promoting
toxic neuroinflammation [61, 62].
A role for the adaptive immune system in neuroin-
flammation and brain pathology has also been proposed
in other (non-Alzheimer’s disease) neurodegenerative
conditions. Removal of CD4+ T lymphocytes, but not
CD8+ lymphocytes, for example, was previously associ-
ated with reduced MPTP-induced neuronal cell loss in a
mouse model of Parkinson’s disease [63]. In contrast, the
same T cell population was shown to provide neuropro-
tection in an animal model of familial amyotrophic lat-
eral sclerosis (ALS) [64, 65]. In this work, mSOD1G93A/
Rag2 ko mice and CD4+ T cell-ablated mSOD1G93A/
CD4 ko mice showed accelerated disease progression
and increased motoneuron degeneration, which was as-
sociated with increased mRNA levels for proinflamma-
tory cytokines and NOX2, and decreased levels of
trophic factors and glutamate transporters [64]. Interest-
ingly, bone marrow reconstitution of mSOD1G93A/Rag2
ko mice with T cells led to a prolonged survival and sup-
pressed cytotoxicity [64]. These beneficial effects were
accompanied by the induction of an M2 protective
microglial phenotype, which was mainly attributed to
the presence of CD4+CD25+FoxP3+ regulatory T lym-
phocytes (Tregs) [65]. Suppressive effects on both the
adaptive and the innate arm of the immune system have
been well documented for Tregs [66–68]. Their lack in
the Rag2-deficient PSAPP transgenic mice may there-
fore, at least in part, account for the observed increased
neuroinflammatory phenotype and microglia-mediated
phagocytosis of Aβ aggregrates. This possibility is further
supported by recent findings in the 5XFAD AD mouse
model of AD, in which transient depletion of Foxp3+
Tregs, or pharmacological inhibition of their activity,
was similarly shown to mitigate amyloid plaque clear-
ance [69]. Tregs secrete various anti-inflammatory cyto-
kines (such as IL-4, IL-10 and IL-13) and have been
shown to promote alternatively activated (M2) responses
and attenuate proinflammatory (M1) microglial re-
sponses [68, 70, 71]. Notably, microglial polarization to-
wards the M1 response has been associated with
reduced amyloid pathology [72, 73], which would also be
in line with our findings in the T and B cell-ablated
PSAPP mice. Despite significantly reduced Aβ levels, an
increased proinflammatory phenotype in the absence of
functional adaptive immune cells may be a double-edged
sword. In fact, proinflammatory microglial responses
have also been associated with detrimental consequences
such as increased tau pathology and exacerbated neuro-
toxicity [73]. In our study, the beneficial effects on
Aβ pathology were not accompanied by a reversal of
hippocampal-dependent memory deficits in the PSAPP/
Rag2 ko mice. Non-transgenic Rag2 ko mice, however,
were equally impaired on two different hippocampal-
dependent tasks in comparison to the WT control, sug-
gesting additional Aβ-independent effects of the T and B
cell ablation on cognitive performance. In line with these
findings, a properly functioning adaptive immune system
has previously been shown to be involved in maintaining
cognitive health and hippocampal memory formation in
several immunocomprised mouse models lacking func-
tional T cells [48–50]. These effects were proposed to be
mainly mediated by non-CNS specific CD4+ T cells play-
ing a role in brain plasticity and promoting neurogenesis
in a BDNF-dependent manner in the adult hippocampus
[48–50].
Conclusions
In summary, the results of our current study demon-
strate an impact of the adaptive immunity on Alzhei-
mer’s disease-related β-amyloid pathology in vivo and
suggest a crosstalk between the adaptive immune system
and microglial cells as a likely underlying mechanism. In
two independent experimental approaches, ablation of
functional T and B cells led to reduced brain Aβ path-
ology and decreased Aβ levels along with increased
microgliosis and clearance of Aβ aggregates. Ablation of
the adaptive immune system, however, did not influence
Aβ levels and glial cells in younger APP transgenic mice
at a pre-plaque stage suggesting that the modulation of
microglial responses to Aβ is specifically related to the
presence of amyloid deposits. Taken together, our find-
ings point to a yet unidentified role of the adaptive im-
munity in modulating and dampening microglial
responses to misfolded Aβ peptides in the brain. From
an evolutionary perspective, this could be a protective
compensatory mechanism of the adaptive immune sys-
tem aimed to control or reduce potentially toxic neu-
roinflammatory responses to Aβ aggregates, even though
at the cost of an increased amyloid plaque deposition.
Future studies will be needed to delineate the specific
lymphocyte subpopulation(s) and major immune media-
tors involved in these processes. A better understanding
of the underlying neuroimmunological mechanisms may
ultimately pave the way for more effective and safer
therapies harnessing adaptive immunity to treat cerebral
β-amyloidosis.
Additional files
Additional file 1: Figure S1. Absence of lymphocytes in both Rag2 ko
mouse lines. 8 month-old Rag2 ko and PSAPP/Rag2 ko mice show
virtually no B cells and CD4+ T cells, whereas age-matched WT and
PSAPP transgenic animals show comparable numbers of B and CD4+ T
cells as determined by FACS staining of CD45+ blood lymphocytes with
Späni et al. Acta Neuropathologica Communications  (2015) 3:71 Page 11 of 14
antibodies against CD4 and the pan B-cell marker B220. In addition, no
significant differences in the myeloid monocytic compartment (Ly6Chigh
and Ly6Cintermediate) are observed among the four genotypes. #p = 0.05-0.1.
*p < 0.05. n = 4–6 per group. (TIFF 41631 kb)
Additional file 2: Figure S2. Lack of amyloid plaque deposition at
3 months. (A) Thioflavin-S staining confirms absence of amyloid plaque
deposition in 3 month-old PSAPP and age-matched PSAPP/Rag2 ko mice
(representative images of cortical stainings are shown). (B) Quantitative
MSD analysis of Aβ40 and Aβ42 in plasma and cortical tissue homogenized
using sequential extraction to obtain different protein fractions: Tris soluble;
SDS detergent soluble; formic acid soluble fraction (B). Statistical analysis
reveals no differences in Aβ levels between PSAPP/Rag2 ko mice and the
PSAPP mice at 3 months. Scale bar = 300 μm. n = 14–15 per group.
(TIF 26755 kb)
Additional file 3: Figure S3. No difference in APP processing at
8 months. (A) Western blot analysis of cortical SDS extracts from
8 month-old mice in comparison to age-matched PSAPP mice. Values
were normalized to GAPDH. (B) Quantification shows no significant
differences in full length APP and APP C-terminal fragments (C99 and
C83) between PSAPP/Rag2 ko and PSAPP mice. n = 7 per group.
(TIF 29174 kb)
Additional file 4: Figure S4. No difference in gliosis at 3 months of
age (A, B) GFAP immunohistological analysis for astrocytes and (C, D)
Iba1 immunostaining for microglia (representative images of cortical
stainings are shown on the left). Statistical analysis reveals no significant
differences in gliosis between the four genotypes at 3 months of age.
Scale bar = 300 μm (Insert: Scale bar = 40 μm). n = 11–13 per group.
(TIFF 158644 kb)
Additional file 5: Figure S5. No difference in Thioflavin S-stained
amyloid deposits between Rag2 ko and WT BM-transferred PSAPP mice.
(A) Representative images of Thioflavin S-stained cortical amyloid deposits.
(B) Quantitative analysis of Thioflavin S stainings 6 months after
transplantation (at the age of 18 months) shows no difference in amyloid
load and amyloid plaque number. Scale bar = 300 μm. n = 8–10 per group.
(TIF 16319 kb)
Additional file 6: Figure S6. No difference in APP processing.
(A) Western blot analysis of cortical SDS extracts from
18-month-old PSAPP mice reconstituted with WT or Rag2 ko BM
6 months before sacrifice. Values were normalized to GAPDH. (B)
Quantification reveals no significant differences in full length APP and APP C-
terminal fragments (C99 and C83). n= 6 per group. (TIF 26355 kb)
Additional file 7: Figure S7. Similar size of amyloid plaques analyzed
by confocal microscopy. (A) Comparable average size of analyzed
amyloid plaques between WT and Rag2 ko BM-reconstituted PSAPP mice
at the age of 18 months. On average 12 Thioflavin S-stained amyloid
plaques per mouse (n = 9 mice per group) were analyzed by laser scanning
confocal microscopy. p = 0.711. (B) Trend towards an increased average
number of Iba1-positive cells per plaque in the Rag2 ko BM-recipient PSAPP
mice in comparison to the WT BM-reconstituted PSAPP mice at 18 months.
Again, on average 12 Thioflavin S-stained amyloid plaques per mouse (n = 9
mice per group) were analyzed by laser scanning confocal microscopy.
#p = 0.086. (TIF 8887 kb)
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